Aditx Therapeutics Inc Stock price
Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,143 stocks worldwide.
Key metrics
Aditx Therapeutics Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a Aditx Therapeutics Inc forecast:
Analyst Opinions
8 Analysts have issued a Aditx Therapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aditx Therapeutics Inc Stock News
Company Profile
ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.
| Head office | United States |
| CEO | Mr. Albanna |
| Employees | 26 |
| Founded | 2017 |
| Website | aditxt.com |


